CDK4/6 and MAPK—Crosstalk as Opportunity for Cancer Treatment
Despite the development of targeted therapies and novel inhibitors, cancer remains an undefeated disease. Resistance mechanisms arise quickly and alternative treatment options are urgently required, which may be partially met by drug combinations. Protein kinases as signaling switchboards are freque...
Main Authors: | Lisa Scheiblecker, Karoline Kollmann, Veronika Sexl |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2020-11-01
|
Series: | Pharmaceuticals |
Subjects: | |
Online Access: | https://www.mdpi.com/1424-8247/13/12/418 |
Similar Items
-
CDK6 Inhibition: A Novel Approach in AML Management
by: Iris Z. Uras, et al.
Published: (2020-04-01) -
CDK 4/6 inhibitors combined with radiotherapy: A review of literature
by: Claire Bosacki, et al.
Published: (2021-01-01) -
CDK4/6 Inhibitors in Melanoma: A Comprehensive Review
by: Mattia Garutti, et al.
Published: (2021-05-01) -
Recent advances of highly selective CDK4/6 inhibitors in breast cancer
by: Hanxiao Xu, et al.
Published: (2017-04-01) -
CDK4/6 inhibitor palbociclib suppresses IgE-mediated mast cell activation
by: Yi-Bo Hou, et al.
Published: (2019-08-01)